Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147

Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.

Om Podcasten

This podcast brings you interviews with journal authors providing insight on their recent publication in an official journal of the American College of Clinical Pharmacy. Pharmacotherapy publishes advances in human pharmacology and drug therapy and the JACCP publishes innovations in clinical pharmacy practice. ACCP JOURNALS DISCLAIM ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR ANY OTHER DAMAGES, INCLUDING LOSS OF PROFITS, ARISING OUT OF ANY USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE THE PODCAST, ITS CONTENTS AND MATERIALS.